There are 398 resources available
82P - Clinical application of a genomic tool for decision support in breast cancer patients in Scotland
Presenter: Adam Peters
Session: Poster Display session
83P - The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2- early and metastatic breast cancer
Presenter: Nabil Dorkhom
Session: Poster Display session
84P - Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on health-related quality of life in breast cancer survivors during adjuvant endocrine therapy
Presenter: Bruna Maria Santos
Session: Poster Display session
85P - Correlation between Prosigna® and three IHC-based surrogate intrinsic breast cancer subtype classifiers: a real world-study
Presenter: Miguel Martin Jimenez
Session: Poster Display session
86P - Change in dietary habits does not affect body composition in early breast cancer patients treated with aromatase inhibitor
Presenter: Lara Laini
Session: Poster Display session
87P - EPClin vs OncotypeDx in invasive lobular cancer (ILC)
Presenter: Ines Leao
Session: Poster Display session
88P - Genetic platforms in hormone receptor (HR) + early breast cancer (eBC). Could logistic regression models be used instead?
Presenter: Assumpcio Lopez Paradis
Session: Poster Display session
89TiP - (Trial in progress) Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with early-stage HER2+ breast cancer in Europe: The ASKHER2 survey
Presenter: Soraia Matos
Session: Poster Display session
90TiP - Adjuvant Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer (EBC), Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6)
Presenter: Giovanna Rossi
Session: Poster Display session
94P - Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
Presenter: Mattea Reinisch
Session: Poster Display session